Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex announced an immediate cost reduction plan cutting its workforce by approximately 60% and winding down all non-clinical R&D to focus resources on the Phase 2b trial of Allocetra™ in knee osteoarthritis. Management salaries are being cut 20%, with CEO Dr. Oren Hershkovitz taking a 40% reduction, in a move the company says is designed to substantially reduce cash burn. Topline six-month data from the Phase 2b trial is expected by mid-2027, building on positive Phase 1/2a results and the FDA's July 2026 RMAT designation.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.